Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 100kWORD 17k
5 October 2018
E-003845/2018(ASW)
Answer given by Ms Malmström on behalf of the European Commission
Question reference: E-003845/2018

The EU and Ukraine have in their Association Agreement agreed on patent rules that reflect the EU legislation and comply with the international provisions in this area. Notably, the provisions in the Agreement ensure innovators’ capacity to build on prior knowledge to develop valuable new and improved treatments (second and further medical indications or new therapies) that can improve health outcomes.

Furthermore, the Agreement recalls the flexibilities provided for by international trade law, notably the right to grant compulsory licenses and the freedom to determine the grounds upon which such licenses are granted in line with the letter and spirit of the World Trade Organisation (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement.

The new Ukrainian draft law on patents would prohibit patents on certain types of biopharmaceutical inventions. The Commission has already raised its concerns about such restrictions at the last EU-Ukraine Intellectual Property Rights (IPR) Dialogue in Kyiv (on 20 June 2018), because they undermine innovation and seem to not comply with Article 27(1) of the WTO TRIPS Agreement.

Last updated: 8 October 2018Legal notice